NO330274B1 - Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein - Google Patents

Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein Download PDF

Info

Publication number
NO330274B1
NO330274B1 NO20031595A NO20031595A NO330274B1 NO 330274 B1 NO330274 B1 NO 330274B1 NO 20031595 A NO20031595 A NO 20031595A NO 20031595 A NO20031595 A NO 20031595A NO 330274 B1 NO330274 B1 NO 330274B1
Authority
NO
Norway
Prior art keywords
peptide
amino acid
vaccine
antigen
acid residues
Prior art date
Application number
NO20031595A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031595D0 (no
NO20031595L (no
Inventor
Frank Mattner
Wolfgang Zauner
Eszter Nagy
Michael Buschle
Jorg Fritz
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of NO20031595D0 publication Critical patent/NO20031595D0/no
Publication of NO20031595L publication Critical patent/NO20031595L/no
Publication of NO330274B1 publication Critical patent/NO330274B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20031595A 2000-10-18 2003-04-08 Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein NO330274B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
PCT/EP2001/012041 WO2002032451A1 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties

Publications (3)

Publication Number Publication Date
NO20031595D0 NO20031595D0 (no) 2003-04-08
NO20031595L NO20031595L (no) 2003-06-05
NO330274B1 true NO330274B1 (no) 2011-03-14

Family

ID=3688953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031595A NO330274B1 (no) 2000-10-18 2003-04-08 Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein

Country Status (26)

Country Link
US (3) US8361476B2 (cs)
EP (1) EP1326634B1 (cs)
JP (2) JP4227407B2 (cs)
KR (1) KR100598302B1 (cs)
CN (1) CN1248736C (cs)
AT (2) AT410635B (cs)
AU (2) AU2002212326B2 (cs)
BR (1) BRPI0114994B8 (cs)
CA (1) CA2426490C (cs)
CZ (1) CZ303303B6 (cs)
DE (1) DE60119145T2 (cs)
DK (1) DK1326634T3 (cs)
ES (1) ES2263668T3 (cs)
HU (1) HU228382B1 (cs)
IL (2) IL154605A0 (cs)
IS (1) IS2608B (cs)
MX (1) MXPA03002828A (cs)
NO (1) NO330274B1 (cs)
NZ (1) NZ524532A (cs)
PL (1) PL209016B1 (cs)
PT (1) PT1326634E (cs)
RU (2) RU2328305C2 (cs)
SI (1) SI1326634T1 (cs)
SK (1) SK287618B6 (cs)
WO (1) WO2002032451A1 (cs)
ZA (1) ZA200301465B (cs)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
CA2433794A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
CN102174533A (zh) 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
EP2287315A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
CA2519922A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
JP2007523609A (ja) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト 表皮ブドウ球菌抗原
EP1615950A2 (en) 2003-04-15 2006-01-18 Intercell AG S. pneumoniae antigens
US8076059B2 (en) * 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
US20080175856A1 (en) 2003-05-30 2008-07-24 Intercell Ag Enterococcus Antigens
EP1648502B1 (en) * 2003-07-11 2010-12-01 Intercell AG Hcv vaccines
ES2297688T3 (es) 2004-03-12 2008-05-01 Intercell Ag Procedimiento para solubizar mezclas de peptidos.
ES2556710T3 (es) 2004-09-24 2016-01-19 Novartis Ag Proteínas capsidiales VP1 modificadas del parvovirus B19
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2007264205B2 (en) 2006-06-28 2013-04-18 Statens Serum Institut Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
CN101490083A (zh) 2006-07-07 2009-07-22 英特塞尔股份公司 小化脓性链球菌抗原及其用途
EP2289906A1 (en) 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2266591A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
EP2489673A3 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
DK2158211T3 (en) 2007-05-31 2016-12-05 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2167530A2 (en) 2007-06-18 2010-03-31 Intercell AG Chlamydia antigens
EP2265634A2 (en) 2008-03-17 2010-12-29 Intercell AG Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
KR101614344B1 (ko) 2008-04-02 2016-04-21 토쿠시마 대학 합성 펩티드를 함유하는 항원약물 비이클과 이것을 사용하는 점막 백신
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2424882A2 (en) 2009-02-05 2012-03-07 Intercell AG Peptides protective against e. faecalis, methods and uses relating thereto
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
PE20110065A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
KR20120089863A (ko) 2009-10-09 2012-08-14 사노피 “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2536427A1 (en) 2010-02-19 2012-12-26 Intercell AG Ic31 nanoparticles
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
PT2575870T (pt) 2010-06-04 2017-02-10 Wyeth Llc Formulações de vacinas
HUE034544T2 (hu) 2010-08-23 2018-02-28 Wyeth Llc Neisseria meningitidis rLP2086 antigént tartalmazó stabil készítmények
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
MX350170B (es) 2010-12-22 2017-08-28 Wyeth Llc Composición inmunogénica estable de antígenos de staphylococcus aureus.
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
KR101784644B1 (ko) 2012-03-09 2017-10-11 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013169922A1 (en) * 2012-05-08 2013-11-14 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
EA039237B1 (ru) * 2012-10-29 2021-12-21 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Применение маннозилированного хитозана в качестве адъюванта в составе вакцин для пероральной или мукозной доставки
MX363512B (es) 2012-12-20 2019-03-26 Pfizer Proceso de glicoconjugacion.
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
JP6948951B2 (ja) 2015-05-04 2021-10-13 ファイザー・インク Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
CN113813231B (zh) * 2016-07-01 2022-06-21 四川大学 抗菌肽衍生物在制备核酸载体中的用途及核酸载体
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
EP3577130A2 (en) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis compositions and methods thereof
WO2018187515A1 (en) * 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
CA3089790A1 (en) 2018-02-16 2019-08-22 2A Pharma Ab Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
WO2020234300A1 (en) 2019-05-20 2020-11-26 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
WO2021202456A1 (en) * 2020-03-30 2021-10-07 The Wistar Institute Of Anatomy And Biology Synthetic soluble receptor mimics and methods of use for treatment of covid-19
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112023017274A2 (pt) 2021-04-09 2023-11-14 Valneva Se Vacina contra metapneumovírus humano
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2168582A1 (en) * 1993-08-06 1995-02-16 John D. Fikes Cloning and characterization of the complete mage-1 gene
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
EP0991767A1 (en) 1997-06-11 2000-04-12 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
AU760034B2 (en) 1997-08-29 2003-05-08 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CA2519922A1 (en) 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
DE602004029657D1 (de) * 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
EP1648502B1 (en) 2003-07-11 2010-12-01 Intercell AG Hcv vaccines

Also Published As

Publication number Publication date
EP1326634B1 (en) 2006-04-26
HUP0302117A3 (en) 2004-11-29
CN1468109A (zh) 2004-01-14
CN1248736C (zh) 2006-04-05
AU1232602A (en) 2002-04-29
BRPI0114994B1 (pt) 2017-11-07
CZ303303B6 (cs) 2012-07-25
NO20031595D0 (no) 2003-04-08
DK1326634T3 (da) 2006-08-14
US20090123486A1 (en) 2009-05-14
CA2426490A1 (en) 2002-04-25
IS2608B (is) 2010-04-15
CA2426490C (en) 2012-01-31
KR100598302B1 (ko) 2006-07-07
PL362966A1 (en) 2004-11-02
ZA200301465B (en) 2004-02-24
DE60119145D1 (de) 2006-06-01
PT1326634E (pt) 2006-09-29
NO20031595L (no) 2003-06-05
AU2002212326B2 (en) 2006-01-05
BRPI0114994B8 (pt) 2021-05-25
BR0114994A (pt) 2003-09-30
US20130216583A1 (en) 2013-08-22
JP2008222721A (ja) 2008-09-25
ATA17892000A (de) 2002-11-15
US8361476B2 (en) 2013-01-29
DE60119145T2 (de) 2007-02-01
AT410635B (de) 2003-06-25
RU2007146372A (ru) 2009-06-20
ATE324116T1 (de) 2006-05-15
US20050063978A1 (en) 2005-03-24
IL154605A0 (en) 2003-09-17
HU228382B1 (en) 2013-03-28
KR20030043993A (ko) 2003-06-02
PL209016B1 (pl) 2011-07-29
EP1326634A1 (en) 2003-07-16
SK287618B6 (sk) 2011-04-05
WO2002032451A1 (en) 2002-04-25
IS6722A (is) 2003-02-20
MXPA03002828A (es) 2003-07-14
IL154605A (en) 2009-05-04
CZ20031299A3 (cs) 2003-10-15
HK1055899A1 (en) 2004-01-30
NZ524532A (en) 2004-10-29
JP4227407B2 (ja) 2009-02-18
WO2002032451A8 (en) 2002-05-23
ES2263668T3 (es) 2006-12-16
SI1326634T1 (sl) 2006-10-31
JP2004511528A (ja) 2004-04-15
HUP0302117A2 (hu) 2003-09-29
RU2328305C2 (ru) 2008-07-10
US8900564B2 (en) 2014-12-02
SK5752003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
NO330274B1 (no) Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein
AU2002212326A1 (en) Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2008222721A6 (ja) ワクチン組成物
AU784403B2 (en) Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
Jiang et al. Synthetic vaccines: the role of adjuvants in immune targeting
Xu et al. Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands
Bolhassani et al. Endogenous and exogenous natural adjuvants for vaccine development
US20070041998A1 (en) Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
Heit et al. Vaccine protocols for enhanced immunogenicity of exogenous antigens
HK1055899B (en) Vaccine composition comprising an antigen and a peptide having adjuvant properties

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VALNEVA AUSTRIA GMBH, AT

MK1K Patent expired